These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 8067283)

  • 21. Carcinogen-DNA and carcinogen-protein adducts in molecular epidemiology.
    Wild CP; Pisani P
    IARC Sci Publ; 1997; (142):143-58. PubMed ID: 9354917
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pyrrolizidine alkaloid-derived DNA adducts as a common biological biomarker of pyrrolizidine alkaloid-induced tumorigenicity.
    Xia Q; Zhao Y; Von Tungeln LS; Doerge DR; Lin G; Cai L; Fu PP
    Chem Res Toxicol; 2013 Sep; 26(9):1384-96. PubMed ID: 23937665
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Protein adducts as biomarkers of human carcinogen exposure.
    Skipper PL; Peng X; Soohoo CK; Tannenbaum SR
    Drug Metab Rev; 1994; 26(1-2):111-24. PubMed ID: 8082561
    [No Abstract]   [Full Text] [Related]  

  • 24. Structural characterization of the major adducts obtained after reaction of an ultimate carcinogen aflatoxin B1-dichloride with calf thymus DNA in vitro.
    Wood ML; Smith JR; Garner RC
    Cancer Res; 1988 Oct; 48(19):5391-6. PubMed ID: 3138022
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Detection of carcinogen-DNA adducts in exfoliated urothelial cells of cigarette smokers: association with smoking, hemoglobin adducts, and urinary mutagenicity.
    Talaska G; Schamer M; Skipper P; Tannenbaum S; Caporaso N; Unruh L; Kadlubar FF; Bartsch H; Malaveille C; Vineis P
    Cancer Epidemiol Biomarkers Prev; 1991; 1(1):61-6. PubMed ID: 1845172
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Carcinogen-DNA adducts as tools in risk assessment.
    Airoldi L; Pastorelli R; Magagnotti C; Fanelli R
    Adv Exp Med Biol; 1999; 472():231-40. PubMed ID: 10736630
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mycotoxins as human carcinogens-the IARC Monographs classification.
    Ostry V; Malir F; Toman J; Grosse Y
    Mycotoxin Res; 2017 Feb; 33(1):65-73. PubMed ID: 27888487
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aflatoxin B1-2,3-oxide as a probable intermediate in the covalent binding of aflatoxins B1 and B2 to rat liver DNA and ribosomal RNA in vivo.
    Swenson DH; Lin JK; Miller EC; Miller JA
    Cancer Res; 1977 Jan; 37(1):172-81. PubMed ID: 187331
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predictive value of molecular dosimetry: individual versus group effects of oltipraz on aflatoxin-albumin adducts and risk of liver cancer.
    Kensler TW; Gange SJ; Egner PA; Dolan PM; Muñoz A; Groopman JD; Rogers AE; Roebuck BD
    Cancer Epidemiol Biomarkers Prev; 1997 Aug; 6(8):603-10. PubMed ID: 9264273
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cancer chemoprotection by oltipraz: experimental and clinical considerations.
    Helzlsouer KJ; Kensler TW
    Prev Med; 1993 Sep; 22(5):783-95. PubMed ID: 8234218
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The importance of carcinogen dose in chemoprevention studies: quantitative interrelationships between, dibenzo[a,l]pyrene dose, chlorophyllin dose, target organ DNA adduct biomarkers and final tumor outcome.
    Pratt MM; Reddy AP; Hendricks JD; Pereira C; Kensler TW; Bailey GS
    Carcinogenesis; 2007 Mar; 28(3):611-24. PubMed ID: 16973675
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quantitation of aflatoxin B1 adduction within the ribosomal RNA gene sequences of rat liver DNA.
    Irvin TR; Wogan GN
    Proc Natl Acad Sci U S A; 1984 Feb; 81(3):664-8. PubMed ID: 6422462
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Environmental and chemical carcinogenesis.
    Wogan GN; Hecht SS; Felton JS; Conney AH; Loeb LA
    Semin Cancer Biol; 2004 Dec; 14(6):473-86. PubMed ID: 15489140
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel uses of mass spectrometry in studies of adducts of alkylating agents with nucleic acids and proteins.
    Farmer PB; Lamb J; Lawley PD
    IARC Sci Publ; 1988; (89):347-55. PubMed ID: 3198219
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Excision of aflatoxin B1-imidazole ring opened guanine adducts from DNA by formamidopyrimidine-DNA glycosylase.
    Chetsanga CJ; Frenette GP
    Carcinogenesis; 1983 Aug; 4(8):997-1000. PubMed ID: 6409445
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Carcinogen-macromolecular adducts as biomarkers in human cancer risk assessment.
    Hsia MT
    Biomed Environ Sci; 1991 Jun; 4(1-2):104-12. PubMed ID: 1910588
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biochemical (postlabelling) methods for analysis of carcinogen-DNA adducts.
    Randerath K; Randerath E; Agrawal HP; Reddy MV
    IARC Sci Publ; 1984; (59):217-31. PubMed ID: 6443609
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Determination of human exposure to the dietary carcinogen 3-amino-1, 4-dimethyl-5H-pyrido[4,3-b]indole (Trp-P-1) from hemoglobin adduct: the relationship to DNA adducts.
    Umemoto A; Monden Y; Grivas S; Yamashita K; Sugimura T
    Carcinogenesis; 1992 Jun; 13(6):1025-30. PubMed ID: 1600606
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular epidemiology in cancer risk assessment and prevention: recent progress and avenues for future research.
    Wogan GN
    Environ Health Perspect; 1992 Nov; 98():167-78. PubMed ID: 1486846
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patterns of DNA adduct formation in liver and mammary epithelial cells of rats treated with 7,12-dimethylbenz(a)anthracene, and selective effects of chemopreventive agents.
    Izzotti A; Camoirano A; Cartiglia C; Grubbs CJ; Lubet RA; Kelloff GJ; De Flora S
    Cancer Res; 1999 Sep; 59(17):4285-90. PubMed ID: 10485473
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.